دورية أكاديمية
أعرض في EDS

Prognostic value of ABO blood groups in upfront operated pancreatic ductal adenocarcinomas.

التفاصيل البيبلوغرافية
العنوان: Prognostic value of ABO blood groups in upfront operated pancreatic ductal adenocarcinomas.
المؤلفون: Joliat GR; Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne (UNIL), Rue du Bugnon 46, Lausanne, 1011, Switzerland. gaetan-romain.joliat@chuv.ch.; Graduate School of Health Sciences, University of Bern, Bern, Switzerland. gaetan-romain.joliat@chuv.ch., Labgaa I; Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne (UNIL), Rue du Bugnon 46, Lausanne, 1011, Switzerland., Martin D; Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne (UNIL), Rue du Bugnon 46, Lausanne, 1011, Switzerland., Vrochides D; Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, Carolinas Medical Center, Charlotte, USA., Schäfer M; Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne (UNIL), Rue du Bugnon 46, Lausanne, 1011, Switzerland.
المصدر: Langenbeck's archives of surgery [Langenbecks Arch Surg] 2024 Sep 18; Vol. 409 (1), pp. 282. Date of Electronic Publication: 2024 Sep 18.
نوع المنشور: Journal Article; Multicenter Study
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 9808285 Publication Model: Electronic Cited Medium: Internet ISSN: 1435-2451 (Electronic) Linking ISSN: 14352443 NLM ISO Abbreviation: Langenbecks Arch Surg Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin : Springer-Verlag, c1998-
مواضيع طبية MeSH: Carcinoma, Pancreatic Ductal*/surgery , Carcinoma, Pancreatic Ductal*/blood , Carcinoma, Pancreatic Ductal*/mortality , Carcinoma, Pancreatic Ductal*/pathology , ABO Blood-Group System* , Pancreaticoduodenectomy* , Pancreatic Neoplasms*/surgery , Pancreatic Neoplasms*/blood , Pancreatic Neoplasms*/mortality , Pancreatic Neoplasms*/pathology, Humans ; Female ; Male ; Aged ; Middle Aged ; Prognosis ; Cross-Sectional Studies ; Disease-Free Survival ; Retrospective Studies ; Survival Rate ; Adult
مستخلص: Purpose: Pancreatic ductal adenocarcinoma (PDAC) has been shown to have a lower incidence in patients with blood group O. It is currently uncertain if patients with group O have a better prognosis after pancreatectomy. This study assessed the overall survival (OS) and disease-free survival (DFS) of PDAC patients who underwent upfront pancreatoduodenectomy based on ABO blood groups.
Methods: A cross-sectional study was performed including patients from two university centers. All consecutive head PDAC patients who underwent upfront pancreatoduodenectomy from 2000 to 2016 were included. OS and DFS were compared between blood groups A, B, AB, and O using Kaplan-Meier curves and log-rank tests.
Results: A total of 438 patients were included (215 women, median age 67). Pre- and intraoperative details were comparable between all subgroups. Median OS did not differ between the four blood groups (A: 23 months, 95% CI 18-28; B: 32, 95% CI 20-44; AB: 37, 95% CI 18-56 and O: 26, 95% CI 20-32, p = 0.192). Median DFS were also similar (A: 19 months, 95% CI 15-23; B: 26, 95% CI 19-33; AB: 35, 95% CI 15-55 and O: 22, 95% CI 15-29, p = 0.441). There was no OS difference between O and non-O groups (median: 26 months, 95% CI 20-33 vs. 25 months, 95% CI 20-30, p = 0.773). On multivariable analysis blood groups were not prognostic of OS. Only lymph node involvement, tumor differentiation, and adjuvant chemotherapy were independent prognostic factors.
Conclusion: OS and DFS were similar between all four blood groups after pancreatoduodenectomy. Independent predictors of OS were associated with tumor characteristics and adjuvant treatment.
(© 2024. The Author(s).)
References: Lancet. 2016 Jul 2;388(10039):73-85. (PMID: 26830752)
HPB (Oxford). 2020 Nov;22(11):1557-1562. (PMID: 32146119)
Anticancer Res. 2018 Oct;38(10):5883-5888. (PMID: 30275214)
Ann Surg. 2013 Jul;258(1):1-7. (PMID: 23728278)
PLoS One. 2012;7(7):e41984. (PMID: 22911869)
PLoS Genet. 2008 May 09;4(5):e1000072. (PMID: 18464913)
Ann Surg. 2022 May 1;275(5):962-971. (PMID: 32649469)
Hum Mol Genet. 2010 May 1;19(9):1863-72. (PMID: 20167578)
J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79. (PMID: 11307091)
Am J Epidemiol. 2013 Jun 15;177(12):1326-37. (PMID: 23652164)
Ann Surg. 2018 Dec;268(6):1058-1068. (PMID: 28692477)
World J Gastroenterol. 2010 Nov 28;16(44):5588-91. (PMID: 21105191)
Ann Surg Oncol. 2021 Dec;28(13):8249-8260. (PMID: 34258720)
J Natl Cancer Inst. 2009 Mar 18;101(6):424-31. (PMID: 19276450)
Arterioscler Thromb Vasc Biol. 2009 Nov;29(11):1958-67. (PMID: 19729612)
HPB (Oxford). 2018 Sep;20(9):848-853. (PMID: 29705345)
Cancer Med. 2017 Jul;6(7):1531-1540. (PMID: 28556564)
BMC Cancer. 2012 Jul 28;12:319. (PMID: 22838843)
Nat Genet. 2009 Sep;41(9):986-90. (PMID: 19648918)
Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188409. (PMID: 32827580)
Ann Surg. 2004 Aug;240(2):205-13. (PMID: 15273542)
Biochim Biophys Acta. 1999 Dec 6;1473(1):247-66. (PMID: 10580143)
Cancer Sci. 2011 May;102(5):1076-80. (PMID: 21306478)
فهرسة مساهمة: Keywords: Pancreas cancer; Pancreatectomy; Pancreatoduodenectomy; Prognosis; Survival
المشرفين على المادة: 0 (ABO Blood-Group System)
تواريخ الأحداث: Date Created: 20240925 Date Completed: 20240925 Latest Revision: 20240928
رمز التحديث: 20240928
مُعرف محوري في PubMed: PMC11424649
DOI: 10.1007/s00423-024-03469-8
PMID: 39320512
قاعدة البيانات: MEDLINE
الوصف
تدمد:1435-2451
DOI:10.1007/s00423-024-03469-8